Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RC278 in advanced solid tumors
NCT07105215Phase 2Recruiting
- Sponsor
- RemeGen
- Start
- Aug 2025
- Primary completion
- Dec 2027
- Modality
- Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 2, open-label trial of RC278 in solid tumor (4 arms), sponsored by RemeGen. Primary endpoints: Dose-Limiting Toxicity at 24 months, Adverse Events/Serious Adverse Events at 24 months and 3 more. Started Aug 2025; status: recruiting.
02
Drugs
RC278
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07105215.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07105215.